



10/15/08 TB WIRE

STOP TB USA was formerly known as the National Coalition for Elimination of Tuberculosis (NCET). **Please pass this information on to your colleagues who are interested in TB elimination.**

CALL FOR ABSTRACTS - North American Region - International Union Against TB and Lung Disease

Dear Colleague: The 13th Annual Conference of the North American Region of the International Union Against Tuberculosis and Lung Disease will be held in February 26-28, 2009 in Vancouver, British Columbia, Canada. The Abstract Committee is calling on submission of abstracts for poster or oral presentations of research on all aspects of tuberculosis control (including epidemiologic, clinical, basic science, nursing, social, behavioral, psychosocial and educational studies) to be presented at the 13th Annual Conference of the North American Region of the IUATLD. Abstracts must be submitted **on or before October 31, 2008**. Abstracts received after this date will not be accepted. Forms are available at www.bc.lung.ca. We will consider only abstracts submitted in accordance with the guidelines. **Travel Grant Award Application:** The committee is now accepting applications for travel grant award for people from North, Central and South America including the Caribbean and Haiti. Forms are available on the above websites. For more information, please contact Dr. Menn Biagtan at 604-731-5864 or at biagtan@bc.lung.ca

Sincerely yours,
Charlie Crane, MD, MPH, Chair, Abstract Committee

THIS JUST IN: PRESIDENT BUSH SIGNS DOMESTIC TB BILL INTO LAW!!

10/14/2008 From Nuala Moore in the American Thoracic Society Washington (ATS) Office: We have reached the final step in enactment of the Comprehensive TB Elimination Act! The President signed the bill into law late yesterday (October 13th). Congratulations all!

The following from STOP TB USA Partners ATS and RESULTS explain some of the key provisions of the new domestic TB legislation:

FROM ATS RECENT WASHINGTON NEWS LETTER: DOMESTIC TB LEGISLATION

This legislation authorizes a 43 percent increase in funding for the Centers for Disease Control and Prevention's Division of Tuberculosis Elimination, including funding for state TB control programs, and expand research on TB prevention, diagnostic, and treatment tools at the CDC and National Institutes of Health. The bill will also intensify efforts to prevent, detect and treat the disease among African-Americans and other minorities and expand detection of TB at the U.S.-Mexico border, as well as treatment of bi-national TB cases..... Thanks to all ATS members who contacted their members of Congress over the past year in support of the Comprehensive TB Elimination Act.

FROM RESULTS: DOMESTIC TB BILL PASSES HOUSE AND SENATE!

Congratulations!The House and Senate both passed the [Comprehensive TB Elimination Act \(H.R. 1532, S. 1551\)](#) by unanimous consent (so there isn't a voting record)..... The final bill authorizes \$200 million for CDC's Division of Tuberculosis Elimination (DTBE) for 2009 and 5 percent increases for years 2010–2013. This is a 43 percent increase in funding for the CDC's DTBE. It authorizes funding for state TB control programs and to expand research on TB diagnostic, treatment and prevention tools at the CDC and NIH. The bill will also intensify targeted efforts to prevent, detect and treat the disease among African Americans and other minorities and expand detection of TB at the U.S.-Mexico border and treatment of binational TB cases. Although the \$200 million authorization level is lower than initially requested, it proved to be the most that the sponsors felt they could achieve in the current fiscal atmosphere. In FY08 the domestic TB funding level was \$140 million, and for FY09, the House recommended \$147 million and the Senate \$140 million (but remember that rather than pass a new budget, a [continuing resolution](#) will extend FY08 funding levels for FY09).

NEW/UPDATED AND RECENTLY RELEASED FROM CDC:

The Self-Study Modules on Tuberculosis are a series of educational modules designed to provide information about tuberculosis (TB) in a self-study format. This course is offered by the Centers for Disease Control and Prevention (CDC), Division of Tuberculosis Elimination (DTBE). The target audiences for this course are outreach workers, nurses, physicians, administrators, health educators, and students from a variety of settings, including TB programs, Managed care organizations, Correctional facilities, Community-based organizations, Homeless shelters, Migrant clinics, Substance abuse facilities, Nursing and medical schools, and other facilities and programs serving persons with or at risk for TB.

TB Patient Educational materials: The culturally appropriate patient education materials cover six topics —TB disease, TB infection, tuberculin skin testing, TB contact investigation, TB and HIV coinfection, and TB medicine. The materials are available in English (low literacy), Spanish, and Tagalog languages. The Spanish and Tagalog versions include the English translations on the flip side of the publication.

Reported Tuberculosis in the United States, 2007. This publication presents the summary data for TB cases reported to CDC, verified, and counted for 2007.

The CDC TB NOTES Newsletter No. 3, 2008:

All of the above are now available at the CDC TB Educational website at:

<http://www.cdc.gov/tb/default.htm>

FROM THE STOP TB GLOBAL PARTNERSHIP

Dear Partners and Friends, We invite you to link to the latest issue of [Stop TB News](#). (http://www.stoptb.org/resource_center/assets/documents/STBNEWSOct08a.pdf)

Warm regards, Judith Mandelbaum – Senior Communications Adviser
Stop TB Partnership Secretariat
World Health Organization
WHO/STB/TBP

RESULTS & TB IN THE NEWS

From RESULTS: Recently, RESULTS took part in a major media event designed to raise awareness of extensively drug-resistant TB. Images taken by renowned photographer James Nachtwey were broadcast

in major public spaces, and featured on [YouTube](#) and [Time](#) magazine. Thousands of people have [signed our online letter](#) urging the presidential candidates to announce a major TB initiative upon taking office. You can help by passing on the links to the slideshow, signing the letter, or writing a [letter to the editor](#) of *Time* thanking them for running the piece.

TB ALLIANCE UPDATE

These are exciting times for the TB Alliance, as it expands to achieve its global mission. Over the last year, we have seen the appointment of our new President and CEO, Dr. Jerome Premmeur, a relocation to a larger New York office, the hiring of Colleen Pero, our first Chief Administrative Officer, and the start of an aggressive recruiting strategy that will fuel the expansion in research and development efforts. Our growing pipeline is anchored by REMoxTB, the Phase III clinical trial of moxifloxacin-containing regimens that was initiated at four sites in Africa this year. REMoxTB is set to expand into Asia and Latin America, with 14 new sites accepted into the trial and expected to begin enrolling over the next few months. Enrollment tracking and projections have made the path forwards clear, and efforts to establish community engagement programs in areas around the trial sites have been intensified. Work to understand and influence market access now encompasses the 22 high burden countries, and our policy work continues to keep the need for new TB drugs high on the political agenda. As we achieve success, we are planning for the needs of the future by building new capabilities important to later stage research and development, such as regulatory and project management expertise. We continue to recruit additional talent in discovery and clinical development to manage the larger portfolio, the new research partnerships formed in 2008, and additional projects that are now closer to the clinical stage of development. Finally, we are forming a dedicated Market Access team to meet the practical challenges of making new drugs and regimens available to those who need them most. In the past three years our spending on research and development has almost tripled, and the pattern of steep growth is projected to continue through 2008 and beyond. With the support and commitment of our partners, the TB Alliance is proud to proclaim its growth and reaffirm its promise to develop new, faster, better TB drugs that will be affordable and adopted.

If you wish to receive the **STOP TB USA** messages at a different e-mail address, or if you no longer wish to receive these messages, please reply to jsegerson@tbcoalition.com

STOP TB USA

1911 Olde Village Run
Dunwoody, GA 30338
Tel: 202-494-2448